Difference between revisions of "Template:Lipid modifying agents"
Jump to navigation
Jump to search
imported>Anypodetos m (Bypass redirect) |
|||
Line 9: | Line 9: | ||
| group1 = [[Cholesterol absorption inhibitor]]s, [[NPC1L1]] | | group1 = [[Cholesterol absorption inhibitor]]s, [[NPC1L1]] | ||
− | | list1 = [[Ezetimibe]] • | + | | list1 = [[Ezetimibe]] • [[SCH-48461]] |
| group2 = [[Bile acid sequestrant]]s/[[Ion exchange resin|resins]] ([[Low-density lipoprotein|LDL]]) | | group2 = [[Bile acid sequestrant]]s/[[Ion exchange resin|resins]] ([[Low-density lipoprotein|LDL]]) | ||
− | | list2 = [[Cholestyramine]] • | + | | list2 = [[Cholestyramine]] • [[Colestipol]] • [[Colestilan]] • [[Colextran]] • [[Colesevelam]] |
}} | }} | ||
Line 22: | Line 22: | ||
| group1 = [[Statin]]s ([[HMG-CoA reductase]], [[Low-density lipoprotein|LDL]]) | | group1 = [[Statin]]s ([[HMG-CoA reductase]], [[Low-density lipoprotein|LDL]]) | ||
− | | list1 = [[Simvastatin]]<sup>#</sup> • | + | | list1 = [[Simvastatin]]<sup>#</sup> • [[Atorvastatin]] • [[Fluvastatin]] • [[Lovastatin]] • [[Mevastatin]] • [[Pitavastatin]] • [[Pravastatin]] • [[Rosuvastatin]] • [[Cerivastatin]]<sup>‡</sup> |
| group2 = Niacin and derivatives ([[High-density lipoprotein|HDL]] and [[Low-density lipoprotein|LDL]]) | | group2 = Niacin and derivatives ([[High-density lipoprotein|HDL]] and [[Low-density lipoprotein|LDL]]) | ||
− | | list2 = [[Niceritrol]] • | + | | list2 = [[Niceritrol]] • [[Niacin]] • [[Nicofuranose]] • [[Aluminium nicotinate]] • [[Nicotinyl alcohol]] • [[Acipimox]] |
}} | }} | ||
Line 34: | Line 34: | ||
| group1 = [[Fibrate]]s ([[PPAR modulator|PPAR]]) | | group1 = [[Fibrate]]s ([[PPAR modulator|PPAR]]) | ||
− | | list1 = [[Clofibrate]]<sup>‡</sup> • | + | | list1 = [[Clofibrate]]<sup>‡</sup> • [[Bezafibrate]] • [[Aluminium clofibrate]] • [[Gemfibrozil]] • [[Fenofibrate]] • [[Simfibrate]] • [[Ronifibrate]] • [[Ciprofibrate]] • [[Etofibrate]] • [[Clofibride]] • [[Clinofibrate]] |
| group2 = [[CETP inhibitor]]s ([[High-density lipoprotein|HDL]]) | | group2 = [[CETP inhibitor]]s ([[High-density lipoprotein|HDL]]) | ||
− | | list2 = [[Anacetrapib]]<sup>†</sup> • | + | | list2 = [[Anacetrapib]]<sup>†</sup> • [[Dalcetrapib]] • [[Torcetrapib]]<sup>§</sup> |
Line 46: | Line 46: | ||
| group7 = Combinations | | group7 = Combinations | ||
− | | list7 = [[Niacin/lovastatin]] • | + | | list7 = [[Niacin/lovastatin]] • [[Niacin/simvastatin]] • [[Ezetimibe/simvastatin]] • [[Laropiprant|Niacin/laropiprant]] |
| group8 = Other | | group8 = Other | ||
− | | list8 = [[Dextrothyroxine]] • | + | | list8 = [[Dextrothyroxine]] • [[Probucol]] • [[Tiadenol]] • [[Benfluorex]] • [[Meglutol]] • [[Omega-3-triglycerides]] • [[Magnesium pyridoxal 5-phosphate glutamate]] • [[Policosanol]] • [[Lapaquistat]]<sup>§</sup> • [[Alipogene tiparvovec]] |
| list9 = {{PharmNavFootnote}} | | list9 = {{PharmNavFootnote}} |